Abstract
Objectives
To describe the efficacy and safety of goniotomy with trabecular meshwork excision using the Kahook Dual Blade (KDB, New World Medical Inc., Rancho Cucamonga, CA) in patients with severe or refractory glaucoma.
Methods
This retrospective multicentre case series reports on 40 eyes with severe or refractory open-angle glaucoma that underwent standalone or combined KDB goniotomy and were followed for 12 months post-operatively in the United-States, Mexico and Switzerland. Surgical success was defined as an intraocular pressure (IOP) reduction ≥20% from baseline at 12 months, with fewer medications than preoperatively. Mean IOP and antiglaucoma medication reduction, probabilities of achieving an IOP ≤16 or 18 mmHg, and adverse events were also analysed.
Results
Mean IOP decreased from 18.1 ± 5.0 mmHg at baseline to 14.8 ± 3.7 mmHg at 12 months (18.2% reduction, P < 0.001). Concomitantly, the mean number of glaucoma medications decreased from 2.5 ± 1.4 to 1.7 ± 1.2 (32% reduction, P = 0.002). The proportion of eyes achieving an IOP reduction of more than 20% from baseline was 37.5% (n = 15) at 12 months. At 12 months, 67.5% and 82.5% achieved a medicated IOP ≤ 16 and ≤18 mmHg, respectively. No severe complications were reported.
Conclusion
Excisional goniotomy with KDB achieves a statistically significant IOP and antiglaucoma medication reduction in severe or refractory glaucoma over a period of 12 months. While its efficacy decreases with time, its favourable safety profile makes it a potentially useful primary or adjunctive procedure in high-risk eyes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 18 print issues and online access
$259.00 per year
only $14.39 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
References
Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. Jama. 2014;311:1901–11.
Mansouri K, Medeiros FA, Weinreb RN. Global rates of glaucoma surgery. Graefes Arch Clin Exp Ophthalmol. 2013;251:2609–15.
Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ, Schiffman JC. Postoperative complications in the Tube Versus Trabeculectomy (TVT) study during five years of follow-up. Am J Ophthalmol. 2012;153:804–14.e1.
Arora KS, Robin AL, Corcoran KJ, Corcoran SL, Ramulu PY. Use of various glaucoma surgeries and procedures in medicare beneficiaries from 1994 to 2012. Ophthalmology. 2015;122:1615–24.
Lavia C, Dallorto L, Maule M, Ceccarelli M, Fea AM. Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: A systematic review and meta-analysis. PloS One. 2017;12:e0183142.
Gillmann K, Mansouri K. Minimally invasive glaucoma surgery: where is the evidence? Asia Pac J Ophthalmol (Philos). 2020;9:203–14.
Gillmann K, Mansouri K, Ambresin A, Bravetti GE, Mermoud A. A prospective analysis of istent inject microstent implantation: surgical outcomes, endothelial cell density, and device position at 12 months. J Glaucoma. 2020;29:639–47.
Wellik SR, Dale EA. A review of the iStent(®) trabecular micro-bypass stent: safety and efficacy. Clin Ophthalmol. 2015;9:677–84.
Chaudhary A, Salinas L, Guidotti J, Mermoud A, Mansouri K. XEN Gel Implant: a new surgical approach in glaucoma. Expert Rev Med devices. 2018;15:47–59.
Schlenker MB, Gulamhusein H, Conrad-Hengerer I, Somers A, Lenzhofer M, Stalmans I, et al. Efficacy, safety, and risk factors for failure of standalone Ab interno gelatin microstent implantation versus standalone trabeculectomy. Ophthalmology. 2017;124:1579–88.
Mansouri K, Guidotti J, Rao HL, Ouabas A, D’Alessandro E, Roy S, et al. Prospective evaluation of standalone XEN gel implant and combined phacoemulsification-XEN gel implant surgery: 1-year results. J Glaucoma. 2018;27:140–7.
Mansouri K, Bravetti GE, Gillmann K, Rao HL, Ch’ng TW, Mermoud A. Two-year outcomes of XEN gel stent surgery in patients with open-angle glaucoma. Ophthalmol Glacoma. 2019;2:309–18.
Gillmann K, Bravetti GE, Rao HL, Mermoud A, Mansouri K. Combined and stand-alone XEN 45 gel stent implantation: 3-year outcomes and success predictors. Acta Ophthalmologica. 2020;99:e531–9.
Gillmann K, Bravetti GE, Rao HL, Mermoud A, Mansouri K. Impact of phacoemulsification combined with XEN gel stent implantation on corneal endothelial cell density: 2-year results. J Glaucoma. 2020;29:155–60.
Mansouri K, Gillmann K, Rao HL, Guidotti J, Mermoud A. Prospective evaluation of XEN gel implant in eyes with pseudoexfoliative glaucoma. J Glaucoma. 2018;27:869–73.
Gillmann K, Bravetti GE, Mermoud A, Rao HL, Mansouri K. XEN gel stent in pseudoexfoliative glaucoma: 2-year results of a prospective evaluation. J Glaucoma. 2019;28:676–84.
Tamm ER. The trabecular meshwork outflow pathways: structural and functional aspects. Exp Eye Res. 2009;88:648–55.
Grant WM. Clinical measurements of aqueous outflow. Am J Ophthalmol. 1951;34:1603–5.
SooHoo JR, Seibold LK, Kahook MY. Ab interno trabeculectomy in the adult patient. Middle East Afr J Ophthalmol. 2015;22:25–9.
Seibold LK, Soohoo JR, Ammar DA, Kahook MY. Preclinical investigation of ab interno trabeculectomy using a novel dual-blade device. Am J Ophthalmol. 2013;155:524–9.e2.
Parekh AS, Tafreshi A, Dorairaj SK, Weinreb RN. Clinical applicability of the International Classification of Disease and Related Health Problems (ICD-9) glaucoma staging codes to predict disease severity in patients with open-angle glaucoma. J Glaucoma. 2014;23:e18–22.
Greenwood MD, Seibold LK, Radcliffe NM, Dorairaj SK, Aref AA, Román JJ, et al. Goniotomy with a single-use dual blade: Short-term results. J Cataract Refract Surg. 2017;43:1197–201.
Dixon MW, Moulin TA, Margolis MS, Palko JR, Mortensen P, Conner IP, et al. Comparative outcomes of the molteno3 and baerveldt glaucoma implants. Ophthalmol Glaucoma. 2020;3:40–50.
Bravetti GE, Mansouri K, Gillmann K, Rao HL, Mermoud A. XEN-augmented Baerveldt drainage device implantation in refractory glaucoma: 1-year outcomes. Graefes Arch Clin Exp Ophthalmol. 2020;258:1787–94.
Arad T, Hoffmann EM, Prokosch-Willing V, Pfeiffer N, Grehn F. XEN-augmented baerveldt implantation for refractory childhood glaucoma: a retrospective case series. J Glaucoma. 2019;28:1015–8.
Salinas L, Chaudhary A, Berdahl JP, Lazcano-Gomez GS, Williamson BK, Dorairaj SK, et al. Goniotomy using the kahook dual blade in severe and refractory glaucoma: 6-month outcomes. J Glaucoma. 2018;27:849–55.
Miller VJ, Young CEC, SooHoo JR, Seibold LK, Kahook MY, Pecen PE, et al. Efficacy of goniotomy with kahook dual blade in patients with uveitis-associated ocular hypertension. J Glaucoma. 2019;28:744–8.
ElMallah MK, Seibold LK, Kahook MY, Williamson BK, Singh IP, Dorairaj SK. 12-month retrospective comparison of kahook dual blade excisional goniotomy with istent trabecular bypass device implantation in glaucomatous eyes at the time of cataract surgery. Adv Ther. 2019;36:2515–27.
Wakil SM, Birnbaum F, Vu DM, McBurney-Lin S, ElMallah MK, Tseng H. Efficacy and safety of kahook dual blade goniotomy: 18-month results. J Cataract Refract Surg. 2020.
ElMallah MK, Berdahl JP, Williamson BK, Dorairaj SK, Kahook MY, Gallardo MJ, et al. Twelve-month outcomes of stand-alone excisional goniotomy in mild to severe glaucoma. Clin Ophthalmol. 2020;14:1891–7.
Sleath B, Blalock SJ, Carpenter DM, Sayner R, Muir KW, Slota C, et al. Ophthalmologist-patient communication, self-efficacy, and glaucoma medication adherence. Ophthalmology. 2015;122:748–54.
Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418–23.
Acknowledgements
Supported in part by the Swiss Glaucoma Research Foundation, Lausanne, Switzerland.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by, Kaweh Mansouri, Kevin Gillmann and Giorgio Enrico Bravetti. The first draft of the manuscript was written by Giorgio Enrico Bravetti. Kaweh Mansouri and Kevin Gillmann commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
JPB: Alcon, Allergan, Bausch and Lomb, CorneaGen, Dakota Lions Eye Bank, Equinox, Expert Opinion, Glaucos, Gore, Imprimis/Harrow Health, JNJ, Kala, Kedalion, MELT Pharmaceuticals, MicroOptix, New World Medical, Ocular Surgical Data, Ocular Theraputix, Omega Ophthalmic, Orasis, Oyster Point, RxSight, Surface Inc., Tarsus, Tear Clear, Vittamed, Vance Thompson Vision, Verana Health (Digisight), Visionary Ventures, Zeiss. Lazcano-Gomez GSL-G: New World Medical. BKW: New World Medical. SKD: New World Medical, Iridex. LS: New World Medical. AAA: New World Medical, Aerie Pharmaceuticals, Bausch and Lomb. AM: Allergan, Bausch and Lomb, Iridex, New World Medical. KM: Santen, Sensimed, Topcon, Alcon, Allergan, Optovue, ImplantData. Others: no financial disclosures.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Bravetti, G.E., Gillmann, K., Salinas, L. et al. Surgical outcomes of excisional goniotomy using the kahook dual blade in severe and refractory glaucoma: 12-month results. Eye 37, 1608–1613 (2023). https://doi.org/10.1038/s41433-022-02196-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41433-022-02196-y